No Data
No Data
CCORF Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Maintains Target Price $18
J.P. Morgan Maintains Travere Therapeutic(TVTX.US) With Buy Rating, Raises Target Price to $20
JP Morgan Maintains Overweight on Travere Therapeutics, Raises Price Target to $20
Express News | Travere Therapeutics Inc : JP Morgan Raises Target Price to $20 From $19
Novartis Gets FDA Approval for Fabhalta in IgAN Patients
Travere Therapeutics to Present at Upcoming Investor Conferences
No Data